P1-0208 — Annual report 2009
1.
Participation in the EU 6th Framework Programme project EUR-INTAFAR (»Inhibition of new targets for fighting antibiotic resistance)

The INTAFAR project (2005-2009) involves 16 partners from 6 EU countries. The funding for UL-FFA (645.000 €) allowed employment of 4 researchers. The aims of the project are understanding biosynthesis of bacterial cell wall as well as design and synthesis of inhibitors of intracellular steps of peptidoglycan biosynthesis. The project is important for the eEuropean health system as the pharmaceutical industry has reduced research efforts in antibacterial drug discovery inspite of growing threat caused by emergence of resistant bacteria. In 2009 the project INTAFAR was in its fifth year.

D.01 Chairing over/coordinating (international and national) projects

COBISS.SI-ID: 2165873
2.
US Patent awarded for novel anticoagulant compounds

US Patent for novel anticoagulant compounds which inhibit thrombin was awarded in 2009 to researchers of the programme team. These compounds are serving as basis for design of novel antithrombotic compounds with dual function

F.32 International patent

COBISS.SI-ID: 2563953
3.
Award of three national patents

The invention relates to dual and triple modulators of integrine receptors alphaVbeta3, alphaIIbbeta, alphaVbeta5 in alpha5beta1 with 1,2,4-oxadiazole and 1,3,5-triazine scaffold (only one patent is cited due to limitation in number of characters).

F.33 Slovenian patent

COBISS.SI-ID: 2611313
4.
Development of patent independent procedure for the synthesis of ezetimibe

Ezetimibe is an important drug used for treatment of hypercholesterolemia. The generic production of ezetimibe represents an oportunity for the Slovenian pharmaceutical industry to compete on American and European markets. There was a need to develop a new economical process for the synthesis of ezetimibe which would provide high yields and at the same time be industrially acceptable. We developed such process in our laboratory and successfully transferred it to the Slovene pharmaceutical industry (Lek).

F.32 International patent

COBISS.SI-ID: 2747249
5.
Five completed PhDs in the programme team during 2009

During 2009 five graduate students in the programme team fiinished their postdraduate studies with PhD. Two of them took postdoctoral positions abroad, two of them remained as researchers at the UL - Faculty of Pharmacy and one of them found a position in pharmaceutical industry (LEK).

D.09 Tutoring for postgraduate students

COBISS.SI-ID: 2542449